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Abstract
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. While the path-
ways that are deregulated in MB remain to be fully characterized, amplification and/or over-
expression of theMYCN gene, which is has a critical role in cerebellar development as a
regulator of neural progenitor cell fate, has been identified in several MB subgroups. Pheno-
typically, aberrant expression of MYCN is associated with the large-cell/anaplastic MB vari-
ant, which accounts for 5-15% of cases and is associated with aggressive disease and poor
clinical outcome. To better understand the role of MYCN in MB in vitro and in vivo and to aid
the development of MYCN-targeted therapeutics we established tumor-derived neuro-
sphere cell lines from the GTML (Glt1-tTA/TRE-MYCN-Luc) genetically engineered mouse
model. A fraction of GTML neurospheres were found to be growth factor independent, ex-
pressed CD133 (a marker of neural stem cells), failed to differentiate upon MYCN withdraw-
al and were highly tumorigenic when orthotopically implanted into the cerebellum. Principal
component analyzes using single cell RNA assay data suggested that the clinical candidate
aurora-A kinase inhibitor MLN8237 converts GTML neurospheres to resemble non-MYCN
expressors. Correlating with this, MLN8237 significantly extended the survival of mice bear-
ing GTML MB allografts. In summary, our results demonstrate that MYCN plays a critical
role in expansion and survival of aggressive MB-propagating cells, and establish GTML
neurospheres as an important resource for the development of novel therapeutic strategies.
Introduction
In children, medulloblastoma (MB) is the most frequently occurring primitive neuroectoder-
mal tumor (PNET) originating in the brain and has been classified into four major subtypes
based on copy number variation and transcription profiles: MBWNT, MBSHH (sonic hedgehog),
MBGroup3 and MBGroup4 [1,2]. Despite the advances made in MB molecular classification, in
the majority of pediatric MB (with the exception of aberrant SHH andWNT pathways)
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oncogenic signaling pathways that are therapeutically targetable remain to be identified. Recent
research has, however, demonstrated that MB harboring MYCN amplification and/or overex-
pression may also be targeted [3]. Amplification of theMYCN gene is associated with a poor
prognosis [4,5], is observed in MBSHH, MBGroup3 and MBGroup4 subtypes [6–10] and is aber-
rantly expressed in the majority of human MB [11]. Despite the growing importance of MYCN
as a therapeutic target in MB, however, we still have a poor understanding of how aberrant
MYCN expression transforms neural stem/progenitor cells to tumors. We previously reported
a genetically engineered mouse model (GEMM) of MYCN-driven MB (GTML: Glt1-tTA/TRE-
MYCN-Luc) in which MYCN expression is controlled by doxycycline (dox) (Tet-off). Using
this system we showed that targeted expression of MYCN induces both classic and large cell
anaplastic (LCA) pathology independent of SHH [11]. Subgroup classification based on gene
expression profiles derived from human medulloblastoma samples in comparison to transgenic
mice suggested that GTML and GTML/Trp53KI/KI mice displayed expression profiles charac-
teristic of human MBGroup3 [3]. Neurosphere lines established from GTML mice proliferate ro-
bustly, express neuronal markers, and form tumors when orthotopically implanted into the
brains of mice [12]. These results suggest that GTML neurosphere cultures contain tumor-
propagating cells, making this a potentially useful system with which the transformative role of
MYCN in MB genesis could be elucidated.
In this context, we conducted a series of molecular and cytological studies to characterize
neurosphere cultures established from GTMLmice. Single cell analysis revealed the expansion
of a homogeneous cell population is dependent on MYCN expression for survival. These spher-
oids are resistant to differentiation, and have features characteristic of partially-committed neu-
ral stem and progenitor cells with MYCN expression, including upregulation of Nestin, CD133,
Otx2, and Musashi, expression of which are associated with maintenance of an undifferentiated
state, and typical of MB-stem/progenitors. Cerebellar implantation of GTML neurospheres sub-
populations showed that tumor propagating-potential resided in CD133+ but not CD15+ or
CD15- cells. Furthermore, treatment of tumors with MLN8237, an aurora-A kinase inhibitor
that induces MYCN oncoprotein degradation [13], effectively extended the survival rate of
GTML mice with aggressive MB. These results clarify the role of MYCN in cellular transforma-
tion and progression of MB, strengthening the hypothesis that MYCN drives the expansion and
enrichment of CD133+ tumor-propagating cells capable of generating aggressive MB.
Materials and Methods
Mouse husbandry
The GTML mouse model has been described previously [11]. All mouse procedures were ap-
proved by the Institute of Cancer Research Ethical Committee following UK Home Office
guidelines (Project License Number: 70/7945). All surgery was performed under anesthetic iso-
flurothane, and all efforts were made to minimize suffering.
Neurosphere isolation and culture
Tissue was isolated from GTML tumors or postnatal P5, P8, P21 cerebellum and midbrain and
transferred into cold HBSS (Invitrogen). The tissues were then cut into 2–3mm2 pieces and en-
zymatically dissociated at 37°C using Liberase Blendzyme 1 (0.62 Wunsch units/ml, Roche) in
PBS for 15–45 min. The enzyme reaction was stopped using 10% volume of Fetal Calf Serum
(FCS, PAA) before the cells were triturated in DMEM/F12 media containing B27 and filtered
through a 70μmmesh. Subsequently the cells were cultured in DMEM/F12 medium (Invitro-
gen) supplemented with 2% B27 supplement (Invitrogen), 20ng/ml epidermal growth factor
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(EGF, Sigma), 20ng/ml fibroblast growth factor (bFGF-basic, Invitrogen) and 100 units/ml
penicillin/streptomycin.
To examine cell division rates, neurospheres were dissociated by pipetting, and cells stained
with trypan blue were counted using a hemocytometer. Alternatively, cells were counted using
the Guava PCA-96 instrument after staining with Guava ViaCount Flex reagent (1:50, Milli-
pore), according to the manufacturers protocol.
For assessment of differentiation potentials, cells were plated onto coverslips coated by
poly-D-lysine (0.1M, Sigma), 0.1% gelatin or laminin (0.5μg–2.0μg/ml, Invitrogen) and grown
under differentiation conditions for up to 14 days. Differentiation medium is composed of
DMEM/F12 medium supplemented with 10% FCS, B27 with or without 1 μg/ml retinoic acid
(Sigma Aldrich). We also plated freshly sorted GTML cells in the presence of 0.5–1.0mg/ml of
collagen (Invitrogen; A1048301) in the pro-differentiation neurobasal media with serum.
Orthotopic implantation
To examine the tumorigenic potential, cells directly obtained from primary tumors, GTML
spheres, or their derivatives were resuspended in neurosphere media and injected into the cere-
bellum of FVB/N female mice: following numbers of cells were implanted: primary tumors
(25 or 100 cells/site), M10519 cells (passages 10–27, 25 to 10,000 cells/site) or freshly sorted
cells (10 cells/site).
Mice aged 6–8 weeks were anesthetized using inhalation of anesthetic isoflurothane. An in-
cision (1cm2) was made in the midline of the scalp over the cerebellum, and a small hole with a
diameter of 1mm was made in the skull using a dental drill at a position 1mm lateral from the
midline and between 1 and 2 mm posterior to the lambdoidal suture avoiding any obvious
blood vessels. Cells were injected at a depth of 2 mm using a 10 μl Hamilton syringe in a stereo-
taxic frame. The needle was left in place for a further 2 minutes to avoid reflux. The needle was
removed gently to avoid dislodging tumor cells. The skull was then sealed using surgical glue.
After the implantation tumor progression was monitored weekly using the IVIS Living Image
System (Caliper Life Sciences) according to the manufacturer’s instructions. Luciferase imaging
was conducted as described previously [11] except that D-luciferin potassium salt (Parkin
Elmer) in PBS was used at 15 mg/kg.
Doxycycline treatment was conducted as described in our previous paper [11]. Briefly, mice
with progressed tumors measured with a signal of 1x109 photons/s were fed with chow (Test-
Diet) containing doxycycline at 200 mg/kg to provide a daily dose of approximately 32 mg/kg.
Tumor burden was determined by bioluminescence.
Immunohistochemistry and Immunocytochemistry
For immunocytochemistry neurospheres were embedded in OCT mounting media (BDH) and
slowly frozen using isopropanol cooled in liquid nitrogen. Then 4μm thick cryosections were
mounted on poly-lysine coated slides (VWR) and fixed with 4% paraformaldehyde (PFA,
Sigma) in PBS for 10 minutes. After subsequent washes with TBS the sections were then
blocked with 10% bovine serum albumin (BSA, Sigma), 15mM glycine (Sigma) and 0.02% Tri-
ton x100 (Sigma) in TBS for 1 hour at room temperature. For mouse antibodies sections were
blocked using the MOM blocking kit (Vector Laboratories) according to the manufacturer’s in-
struction. Sections were incubated with primary antibody overnight in blocking solution (0.1%
BSA-PBS) at room temperature and after subsequent washes with TBS slides were labelled
with secondary antibodies conjugated with Alexa Fluor (1:500, Molecular Probes). Slides were
counterstained with DAPI (Sigma) and then were mounted with Fluoromount G (Southern
Biotech).
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For immunohistochemistry, tumor samples were fixed in 4% paraformaldehyde in PBS for
24hrs to 7days. Samples were decalcified with 0.3M EDTA and then processed using the Leica
ASP300S tissue processor to create a paraffin wax block. Sections were cut at 4μM for hematoxy-
lin and eosin staining and immunohistochemistry was conducted as previously described [14].
Antibodies used for immunohistochemistry and immunocytochemistry were: MYCN (OP-
13, Calbiochem), Ki67 (556003, BD Pharmingen), GFAP (Z0334, DAKO), CD15 (332778, BD
Bioscience), Tuj1 (BAM1195, R&D), Cleaved Caspase 3 (9664, Cell Signaling).
Immunoblot analysis
Neurospheres were cultured under normal and differentiation conditions in the presence or
absence of 1μg/ml doxycycline. Spheres were harvested, and then suspended in cell lysis buffer
(Cell Signaling Technology) according to manufacturer’s protocol. Immunoblot analysis was
performed as described [14]. Following antibodies were used: MYCN (OP-13, Calbiochem),
c-MYC (SC-40, Santa Cruz), Nestin (ab5968, Abcam), beta-actin (4967, Cell Signaling Tech-
nology) and GAPDH (2118, Cell Signaling Technology).
Flow cytometry and fluorescence-activated cell sorting
For cell cycle analyses, GTML spheres were treated with 1μg/ml doxycycline and samples were
taken at 0, 2, 4, 6, 8, 24, and 48 hours. The samples were fixed using 70% ice-cold ethanol, and
then were stored at 4°C for at least 30 min. Then cells were stained with propidium iodide (PI)
(40μg/ml, Invitrogen) at 37°C for 30 min, and then were stored at 4°C for 24 hours. Cell cycle
profiles were analyzed using a Becton Dickinson LSR II fluorescence-activated cell analyzer.
To isolate the CD15+ and CD15- or CD133+ and CD133- populations, M10519 GTML neu-
rospheres were dissociated into single cells, and then were stained with anti-CD15 conjugated
with FITC (1:100, Millipore) or anti-CD133 conjugated with PE (1:100, Miltenyi Biotec) for at
30 min on ice, washed with PBS containing 0.3% Bovine Serum Albumin with antibiotics. Cells
were then counterstained with 0.5μg/ml of DAPI in PBS and sorted through a Becton Dickinson
FACS Aria. Cells were sorted into DMEM/F12 media containing growth factors and B27. The
purity of each population was assessed at the end of each sort using the same analyzer.
Purification of CD133+/- cells using magnetic beads
M10519 GTML neurospheres were dissociated into single cells using the Neurosphere Dissocia-
tion kit P (Miltenyi Biotec) following manufacturer’s instruction. After the dissociation, cells
were centrifuged at 500xg for 10min and then pellet was resuspended in 1ml of PBS supple-
mented with 2%FBS and 1 mM EDTA (sorting buffer). Isolation of CD133+ and CD133- popu-
lations was initially performed through magnetic separation (Easysep, Stemcell Technologies),
followed by a final purification step using the FACS ARIA (BD Biosciences). Cell suspension
(0.5ml, 2x107 cells) was incubated with 50μl of anti-CD133 (Prominin-1) PE-conjugated anti-
body (Miltenyi Biotec) or anti-IgG1 conjugated with PE (Miltenyi Biotec) for 10 min at 4°C.
Cells were then washed with sorting buffer and incubated with 100μl of PE-selection cocktail
(EasySep PE selection kit, Stemcell Technologies) per 1ml of sorting buffer for 15 min at room
temperature following addition of EasySep 50μl nanoparticles per 1ml of cell suspension prior
to magnetic separation. To improve the purity, the magnetic separation process was repeated
total three times. The purity of bead-bound or -unbound fractions was assessed using the FACS
LSRII analyzer (BD Biosciences). Both CD133+ and CD133- fractions were further purified
from bead-bound and—unbound fractions, respectively, using the FACS ARIA (BD Biosci-
ences). 7AAD (Beckman Coulter) was used to exclude dead cells in FACS analyses. Live cells
were counted with trypan blue staining prior to orthotopic implantation (10 cells per site).
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Limited dilution analysis
The M10519 cells (100, 10, and 1 cell(s) per 100 μl of neurobasal media in the presence of
growth factors) were plated into a 96 well plate for prolonged culture. The cells were monitored
bi-weekly to assess sphere formation, and then the final estimate was made approximately 4
weeks post seeding.
Primers for single cell assays
For this study, we initially designed 48 primers for (i) factors that are expressed in three distinct
MB subtypes [5,15–17], (ii) known neural stem cell markers, (iii) known cancer markers and
(iv) MYCN targets. We examined these together with 93 primers we used for mouse embryonic
stem cells in our previous studies [18,19] for primer validation using cDNA from GTML and
mouse embryonic stem cells. Out of 141 primers, we selected 96 primers that passed the primer
validation, the process of which has been described previously [18].
Cell sorting for single cell assays
The accuracy of sorting process was determined as follows. First, 2x105 cells were stained using
0.4μl Carboxyfluorescein diacetate N-succinimidyl Ester (CFSE) fluorescent dye (Sigma Al-
drich), and single cells were sorted using a cell sorter Becton Dickinson into AG480F slides
(Beckman Coulter). Then the presence of labeled cells was inspected under a fluorescent mi-
croscope CKX41 (Olympus) to confirm that only one cell was spotted at a reaction site of the
slide. If two cells were found at a single reaction site, calibration of the sorting machine was re-
started from the beginning. Once sorting accuracy was confirmed, sample cells were labeled
with propidium iodide, sorted into PCR tubes, and then frozen. Cells were then thawed on ice
to disrupt the cell membranes.
Reverse transcription and target-specific amplification
The experimental detail is described in our previous paper [18]. Briefly, reverse transcription
and cDNA amplification were conducted as follows. The reaction was incubated at 50°C for
15 minutes, 95°C for 2 minutes, followed by 18 cycles of 95°C for 15 second and 60°C for 4
minutes. Unincorporated primers were subsequently removed by treating with Exonuclease I
(Exo I, NEB). A reaction mixture contains 10 μl of amplified cDNA, 0.4μl of 10 x Exo I buffer,
0.8μl Exo I enzyme (20u/μl), and 2.8μl of RT-PCR grade water. Reaction was held at 37°C for
30 min, then at 80°C for 15 minutes to inactivate of Exo I. Finally, DNA Suspension Buffer
(36μl) was added to each sample (total 50μl).
Analyses using BioMark system
Experimental details are described in our previous papers [19] [18], except that we used 96x96
Gene Expression IFC Array plates (Fluidigm Corporation) in this study. Sample and primer
mixtures were loaded separately to inlets located on both sides of the array. A BioMark qPCR
reaction mix was composed of 2.5μl of 2xTaqMan Gene Expression Master Mix (Applied Bio-
systems), 0.25μl of 20x DNA Binding Dye Sample Loading Reagent (Fluidigm Corporation),
0.25μl of 20x EvaGreen DNA binding dye (Biotium) and 2μl of Exo I-treated cDNA sample. A
primer reaction mix was composed of 2.5μl of 2xAssay Loading Reagent, 1.25μl of DNA Sus-
pension Buffer, and 1.25μl of a 20μM primer pair. Sample loading was done according to the
instruction manual of the BioMark system.
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Data validation
To evaluate the formation of non-specific amplification products due to primer-dimer forma-
tion or non-specific annealing, we conducted melting curve analyses for each primer as previ-
ously described [18].
Statistical analysis
Cq values higher than the threshold for reliable Cq values (Cqthreshold, S1 Table) were omitted
from the statistical analyses as described [18]. Principal component analysis and hierarchical
clustering analysis (Ward’s method) were conducted using R. It should be noted that for cluster-
ing analyses and principal component analysis, Cq values higher than Cqthreshold were treated as
unreliable values, and thus were all replaced with Cqthreshold+1d. The Kolmogorov-Smirnov test
was used to evaluate the differences of correlation coefficient distributions of data sets derived
from two sample sets, due to the presence of skewness of the distribution and uneven number of
observations between compared groups, both of which were not suitable for conducting stron-
ger tests. The Log-rank test was used to evaluate the difference of the survival distributions of
two sample groups.
Results
Establishment of GTML neurosphere lines
In this study we aimed to identify tumor-propagating cells in MB, and to establish an efficient
pre-clinical study system to examine the potential of small molecules in preventing tumor devel-
opment. We utilized the Glt1-tTA/TRE-MYCN-luciferase (GTML) transgenic mouse model, in
which suppression of humanMYCN and luciferase is achievable in a dox-dependent manner in
brain tissue [11,12] (S1 Fig.). In this system, tumor development is preventable by dox, and
tumor progression is visible using in-vivo bioluminescent imaging (S1 Fig.); both tumor burden
and in vitro cell growth is linearly correlated with luciferase signal intensity (S1 Fig.) [11].
Primary tissues were surgically isolated from growing tumors monitored by weekly lucifer-
ase imaging (Fig. 1A and S1 Fig.). The excised tumors were dissociated and cultured in serum-
free neurobasal media containing EGF and bFGF [20], and established neurospheres within
3–7 days (Fig. 1A), in contrast to explants of midbrain or cerebellum from wild type mice
(which had a limited life span of 7–10 passages). Cells established from at least 6 different pri-
mary tumors at various ages were immortal and exhibited a doubling time of approximately
24 hrs. (S2 Table and S1 Fig.). Taken together these data suggest the existence of a highly prolif-
erative, transformed cell most likely driven by MYCN transgene expression.
To examine the role of MYCN in the growth of GTML cells, we treated M10519 GTML neu-
rospheres (as well as additional cell lines, see S2 Fig.) with dox, and found clear evidence that
growth is dependent on MYCN (Fig. 1B). Cell cycle analyses using flow cytometry showed
clear accumulation of growth-restricted cells in G1 phase, within 4 to 6 hours of treatment
(Fig. 1C), Growth restriction was coincident with complete suppression of MYCN, but not c-
Myc protein (S1 Fig. and S3 Fig.), reduced levels of Ki67, a proliferation marker, and Nestin, a
neural stem and/or progenitor marker, at 48 hours after withdrawal of MYCN (Fig. 1D and
S1 Fig.). Interestingly, in contrast to our previously-established GTML lines with wild type
Trp53 [12], arrested GTML cells rapidly expanded after removal of dox (S1 Fig.), suggesting
that MYCN withdrawal is cytostatic in a fraction of these cells and that growth arrest is revers-
ible. The inconsistency among the GTML cells utilized in the two studies may be due, at least
in part, to the fact that all of GTML cells established in the present study harbor spontaneous
mutations in the region of the Trp53 gene encoding the p53 DNA-binding domain [3]. We
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undertook analysis to establish whether compensatory upregulation of mouse c-Myc protein is
involved in the release from cell cycle arrest and found that c-Myc levels were constant (S1 Fig.
and S3 Fig.), suggesting that at least in our neurosphere cultures, c-Myc does not compensate
for the reduction of MYCN (as previously reported to occur in neural progenitors [21]). Clono-
genic potentials of M10519 cells, one of GTML lines, were examined through secondary sphere
assays, showing that 42% of single M10519 cells were capable of forming spheres in culture
(S4 Fig).
MYCN expression drives expansion of cells expressing markers typical
of neural stem and/or progenitor cells and MB
To characterize GTML neurospheres, we examined the expression of neural stem/progenitor cell
markers by immunocytochemistry. We found that Nestin, a marker for neural stem/progenitor
cells, and the proliferation marker Ki67 were expressed in GTML neurospheres in a MYCN-
Fig 1. Characterization of GTML spheres. (A) Establishing GTML spheres in culture. Primary cells were isolated from GTML tumors, which were identified
through the bioluminescence signals (upper left) and morphology, and were then dissociated into single cells. M10519 GTML neurospheres cultured after
10 days are also shown. Scale bar: 100μm. (B) Effect of MYCNwithdrawal on cell growth. M10519 GTML spheres were seeded at density of 1x105 cells/ml
in the presence of absence of 1μg/ml of dox, and the proliferation of spheres were measured byWST-1 metabolic assay. Error bars, ±SD. (C) Effect of MYCN
withdrawal on cell cycle. M10519 GTML neurosphere were treated with dox prior to cell cycle analyses using FACS. (D) Western analyses. M10519 GTML
spheres were cultured with 1μg/ml of dox.
doi:10.1371/journal.pone.0119834.g001
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dependent manner (Fig. 2A). Expression of a neuron-specific progenitor marker Tuj1 [22] was
not however visibly altered by MYCN withdrawal (Fig. 2A), implying that depletion of MYCN
does not dramatically affect the degree of differentiation in culture. In contrast to our previous
observation in GTML tissues [11], no prominent decrease of Cleaved Caspase 3, a marker of apo-
ptosis, was observed upon MYCNwithdrawal (Fig. 2A and S3 Fig.). To obtain a more detailed
picture of gene expression at the single cell level, we analyzed a M10519 line (we found GTML
lines we established in this study were remarkably similar) using 96-plexed single cell qRT-PCR
(S5 Fig. and S6 Fig.). This analysis indicated that commonmarkers for MB and neural stem cells
including NeuroD1 [23], CD133 (Prominin 1) [24–27], Otx2 [11,28], and Musashi [29] were
downregulated by MYCNwithdrawal (Fig. 2B and S5 Fig.). The frequency of cells expressing
markers including CD133 andMusashi was also decreased by dox, while other stem cell markers
including Sox2 were unaffected by MYCNwithdrawal (Fig. 2C and S5 Fig.). Expression of mark-
ers for astrocytes and ependymal cells (GFAP) [30], astrocytes (S100b) [31], granule neuron pro-
genitors and glioma (Olig2) [32–34] were barely detectable (S5 Fig.) or rarely observed (S5 Fig.)
in single cell analyses. Correlating with the rapid growth in culture, MYCN expression up-regu-
lated master regulators for cell cycle progression, E2F1 and E2F2, both of which are MYCN tar-
gets [35] (S5 Fig.). CD133, a marker for S, G2, andM phases of neural stem cells [36] (Fig. 2B
and 2C). MYCN, as expected, was barely detectable in M10519 cells treated with dox (Fig. 2B
and 2C). Taken together, these results suggest that MYCN expression results in the expansion of
cells with markers typical of neural stem cells and/or progenitors associated with
MB tumorigenesis.
96-gene (see S3 Table and Janos et al [19]) expression profiles for 96 single M10519 cells dis-
played a degree of heterogeneity (S6 Fig.). Single cell BioMark HD expression data are shown in
S3 Table. To evaluate the difference of correlation coefficient distributions of data sets derived
from two populations, using the Kolmogorov-Smirnov test we calculated pairwise correlation
coefficients of expression levels for 96 genes in a given cell population. The mean correlation co-
efficient (r̄) for M10519 neurospheres was 0.77, and the difference between M10519 cells and
WT1 (r̄ = 0.71, NM10519 = 1081, NWT1 = 990, D = 0.2662, P = 2.2x10
-16) or WT2 (r̄ = 0.60,
NM10519 = 1081, NWT2 = 990 D = 0.57, P = 2.2x10
-16) cells was statistically significant. These
data indicate that while the expression profiles of individual cells in the M10519 neurosphere
population are not entirely homogeneous in nature, the transcription profiles among cells in
WT1 andWT2 neurosphere cultures derived from normal cerebella are significantly more het-
erogeneous. Furthermore, MYCN withdrawal resulted in a significant reduction of the heteroge-
neity index (r̄ = 0.69, NM10519 = 1081, NM10519+Dox = 990, D = 0.27, P = 2.2x10
-16). Taken
together, these results suggest that MYCN expression elevates the level of cellular homogeneity
and expands cells with neural stem and progenitor markers.
MYCN drives expansion of cells resistant to differentiation stimuli in
culture
Interestingly, despite the stem cell and/or progenitor-like transcription profile of the expanded
cells in neurosphere cultures, GTML cells expressing MYCN displayed only limited differentia-
tion potential in vitro. Following 8 days of growth in serum-containing pro-differentiation
media, we found that three GTML lines retained morphological features typical of undifferenti-
ated cells (S2 Fig.), although we found that the neural stem/progenitor marker Nestin was
downregulated after 2 days of MYCN withdrawal (Fig. 1D). By contrast, the same conditions
induced differentiation of neurospheres established from wild type cerebella (S2 Fig.). The ap-
parent loss of differentiation potential in GTML cells suggest that genetic or epigenetic change
may occur after prolonged MYCN activation. We also found that GTML cells failed to fully
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differentiate under a variety of conditions (e.g. treatment with retinoic acid, a strong inducer of
differentiation (S2 Fig.), or culturing in media containing 0.5mg–1mg/ml of collagen (data not
shown)). When M10519 cells were grown in pro-differentiation media containing serum and
retinoic acids, while we observed the downregulation of MYCN, which is controlled by the
Glt1 promoter that is activated in progenitors, and Nestin at 48–96 hours, we observe no con-
siderable changes in the levels of neuronal markers Synaptophysin and Tuj1 and glial marker
Fig 2. Expression of neuronal, proliferation, and/or MBmarkers in GTML spheres. (A) M10519 GTML spheres were treated with or without dox for 17
days. Immunofluorescence analysis was performed on cryosectioned spheres with anti-Ki67, anti-Nestin, or anti-Tuj1, anti-GFAP, and anti-c-Caspase 3
together with anti-MYCN. Nuclei were counterstained with DAPI. Bar, 50μm. (B) A heat map for averaged expression levels (Cq values, n = 96) of 13 neural
stem cell genes are shown. (C) Percentages of cells expressing CD133, Musashi, Sox2, MYCN, and CD15 are shown. We examinedWT1 andWT2 cells
(see the text), untreated M10519 spheres (M10519), M10519 spheres treated with dox for 24 hours (Dox), or M10519 spheres treated with MLN8237 for 24
hours (MLN8237).
doi:10.1371/journal.pone.0119834.g002
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GFAP (S3 Fig.). Taken together, these results suggest that MYCN expression results in the en-
richment of cells with markers typical of stem and/or progenitor cells, driving expansion of
highly proliferative cells resistant to differentiation stimuli. The apparent loss of differentiation
potential in GTML spheres is in contrast with neurospheres derived from human MB (for
whichMYCN status was not examined) [27] or the Ptc-/- mouse model [37], suggesting that
persistent expression of MYCN drives irreversible commitment to expansion of cells with neu-
ral stem and progenitor markers.
MYCN-driven GTML neurospheres retain properties of primary tumors in
vivo
We recently showed that neurospheres derived from GTML mice are capable of forming tu-
mors in a MYCN-dependent manner when orthotopically implanted in the cerebella of non-
transgenic littermates [12]. As expected, the addition of dox to diet rapidly reduced biolumi-
nescence (Fig. 3A) and tumor burden (Fig. 3B) in mice implanted with M10519 cells. To evalu-
ate the impact of MYCN withdrawal in vivo, we examined expression of biomarkers in
orthotopic tumors. Immunohistochemical analysis (Fig. 3C) showed that tumor regression in-
duced by MYCN withdrawal correlated with the loss of expression of the Ki67 proliferation
marker. While GTML cells grow as neurospheres in culture even in the presence of differentia-
tion inducers (S2 Fig.), in a tissue environment 26 days post-initiation of dox treatment, levels
of the glial marker GFAP were elevated, the staining pattern of neuronal marker Tuj1 was al-
tered to a mosaic “salt and pepper” fashion, and MYCN displayed increased cytoplasmic locali-
zation (Fig. 3C). Interestingly, CD15 (SSEA-1/Lex), a putative marker for medulloblastoma in
Ptc1mutant mice [38,39], also displayed elevated and distributed staining profiles upon
MYCN withdrawal. We did not find the elevation of c-Caspase 3, a marker for apoptosis, by
MYCN withdrawal suggesting that the tumor regression by MYCN withdrawal was caused by
mechanisms other than increasing levels of cell death, with cell-cycle arrest and induction of se-
nescence likely candidates [11]. These results suggest that in the tissue environment tumor re-
gression by MYCN withdrawal is involved in partial differentiation and loss of proliferation,
but is not associated with apoptotic cell death.
Tumorigenic potential of GTML neurospheres resides in CD133+ cells
While the cancer stem cell hypothesis predicts that only a minority of cancer cells within a
tumor are usually endowed with tumorigenic potential, our orthotopic implantation assay sug-
gested that both primary tumor and GTML spheres comprise large number of cancer-propa-
gating cells (S7 Fig.). Limiting dilution experiments established an 80% or 50% efficiency for
tumor formation from as few as 100 implanted GTML (passages 10–27) or primary tumor cells
(S7 Fig.), suggesting that MYCN acts to expand a cancer propagating cell within neurosphere
cultures. We compared M10519 (passage 13) and M14942 lines (passage 11) and the difference
in tumor incidence following orthotopic implantation was not statistically significant (Log-
rank test, P = 0.4480) (S7 Fig.). Both neurosphere lines remained highly tumorigenic after 20
passages (data not shown).
To identify cancer-propagating cells enriched in neurospheres, we performed flow cytome-
try for CD133 and CD15, two neural stem cell surface antigens that have been identified as
markers of tumor-propagating potential in MB [25,27,38,39]. Given that our single cell expres-
sion data suggested that both CD15 and CD133 were considerably upregulated by MYCN ex-
pression in M10519 GTML neurospheres (S5 Fig. and S6 Fig.), we examined whether
expression of either marker was associated with tumor-forming potential. Fluorescence activat-
ed cell sorting (FACS)-based CD15 expression revealed that when MB cell populations positive
Characterization of MYCN-Dependent Medulloblastoma
PLOSONE | DOI:10.1371/journal.pone.0119834 March 18, 2015 10 / 20
or negative for this marker were orthotopically implanted, survival was not significantly altered
for either the M10519 (P = 0.9157, Log-rank test) or M0983 (P = 0.8172, Log-rank test) neuro-
sphere cell lines (S8 Fig.). The in vivo results correlated with in vitro data showing that CD15
and CD15 status had no significant effect on self-renewal and neurosphere formation in vitro
(S8 Fig.). In contrast to CD15, FACS sorting of M10519 neurosphere cells based on CD133 ex-
pression (S9 Fig.) revealed a significant effect on the tumor-propagating potential of orthotopi-
cally implanted cells. Serial dilution revealed that mice implanted with 10 CD133+ cells
developed tumors in contrast to CD133- cells, which were significantly less efficient (Log-rank
test, P = 0.0197) (S9 Fig.). Again, these results mirrored in vitro data showing that neurosphere
cells isolated on the basis of CD133 expression exhibited enhanced self renewal and ability to
form neurospheres in vitro (S9 Fig.).
Fig 3. Characterization of GTML orthotopic tumors. (A) M10519 GTML spheres (passage 10–27) were orthotopically implanted into the cerebellum of
FVB/N mice, and tumor development was monitored by bioluminescence. Once bioluminescence signal were reached at 5x109 photons/s the tumors were
either treated with dox to induce MYCNwithdrawal or left untreated (n = 6 per treatment arm) and then the level of luciferase expression was monitored until
day 26. (B) H&E staining of orthotopic tumors. Mice were treated with dox on day 1 (left panels) on tumors with 5x109 photons/s. Tumor regression at day 26
is shown (right panels). Bars, 500μm (upper panels) and 20μm (lower panels). (C) Immunoperoxidase staining of paraffin-embedded orthotopic tumors.
Tumors generated after the implantation of M10519 cells were harvested, paraffin-embedded, sectioned, and labeled with antibodies shown. Sections were
counter-stained with hematoxylin. Bar, 20μm.
doi:10.1371/journal.pone.0119834.g003
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Given that single cell expression analysis showed that the great majority of M10519
GTML cells expressed CD133 (Fig. 2C), it was possible that a small number of contaminating
CD133+ cells in the CD133- fraction were responsible for residual tumor forming activity
(S9 Fig.). To address this issue we sought to obtain more highly purified CD133+ and CD133-
populations through anti-CD133 antibody-based magnetic separation followed by FACS
(Fig. 4A). Purified CD133+ or CD133- cells were then implanted into the cerebellum of FVBN
mice (10 cells per site). Mice implanted with CD133+ cells developed aggressive tumors within
50 days (n = 10) (Fig. 4B), in contrast to mice implanted with CD133- cells, which failed to de-
velop tumors (n = 10) (Fig. 4C, P = 0.0017, Log-rank test). Taken together, these results suggest
that MYCN acts to clonally expand highly proliferative tumor-propagating cell in GTML neu-
rospheres resembling a stem and/or progenitor-like cell marked by CD133 positivity.
Pharmacologic inhibition of MYCN is effective against GTML MB
Amplification of bothMYC andMYCN occurs in poor-outcome MBGroup3 andMBGroup4 [6–10].
MYCN expression is also induced by SHH signaling and as such is highly expressed inMBSHH
[1,12,15,40–43]. Drugs that interfere with MYC family oncoprotein stability or function have
Fig 4. Tumor-propagating potential of CD133+ cells. (A) Purification of CD133+ and CD133- cells. M10519 cells (passage 13) were stained with anti-IgG1
or anti-Prominin-1 (CD133) conjugated with PE prior to purification. Stained cells were first separated into bead-bound and bead-unbound fractions by
magnetic beads conjugated with anti-PE (middle panels). Then each fraction was further purified by FACS sorting. (B) Orthotopic tumors generated after
implantation of CD133+ cells (10 cells per mouse). Sections were stained with hematoxylin and eosin. Bars, 1000μm (upper), 50μm (lower). (C) Kaplan-
Meier curves for overall survival of mice implanted with 10 CD133+ (red, n = 10) or CD133- (blue, n = 10) M10519 cells per site.
doi:10.1371/journal.pone.0119834.g004
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therefore been suggested as potential therapeutic strategies to treat these MB subtypes. We there-
fore examined the effect of an Aurora-A kinase inhibitor MLN8237 on GTMLMB. Aurora-A as-
sociates with MYCN, preventing Fbxw7-mediated proteasomal degradation of MYCN [44]. Our
previous results in neuroblastoma cell lines suggested that MLN8237 blocks the interaction be-
tween Aurora A andMYCN, exposing MYCN to proteasomal degradation [13]. MLN8237 is ef-
fective in MYCN-driven transgenic mouse models of neuroblastoma (TH-MYCN), in which
high-level expression of MYCN is driven in neural crest by a tyrosine hydroxylase (TH) promot-
er [13,45]. Recently Lehman’s group and we have independently shown that MLN8237 given to
mice with tumors penetrated through the blood-brain barrier [3,46], causing the reduction of
MYCN levels in brain tissues.
Single cell expression studies suggested that MLN8237 reduces the probability (Fig. 2C) and
rate (Fig. 2B) of expression of CD133 similar to dox, suggesting that both effects may similarly
diminish the tumor-propagating potential of GTML cells. To evaluate the global impact of
MLN8237 on the transcription profile of M10519 GTML line, we conducted principal compo-
nent analysis (PCA) with single cell expression data. Single cell expression data obtained from
wild type neural cells from midbrain (WT1) and from cerebellum (WT2), untreated M10519
cells, compared to cells in which MYCN is targeted either genetically (with dox) or with
MLN8237 revealed that cells segregated into two or more subgroups discriminated on the PC1-
/PC2 axis. On the PCA projection, WT clusters (WT1 and WT2 cells) were located in close
proximity, but distanced from the (untreated) M10519 cell cluster. M10519 cells form a distin-
guished cluster along the PC1 axis, as well as dox- and MLN8237-treated cells formed partially
overlapping clusters (Fig. 5A). This profile correlated with the result obtained from a hierarchi-
cal clustering analysis. Clusters derived fromM10519 cells can be divided into three sub-
groups: untreated M10519 cells only, dox-treated M10519 cells only, and cells treated with dox
or MLN8237 (S10 Fig.). The first cluster is located away from the second and third clusters,
which are more similar to each other. The relatively close distance between M10519 cells+dox
and M10519 cells+MLN8237 in two clustering analyses suggested MLN8237 affects regulatory
pathways regulated by MYCN. Similar to dox-treated cells, known MYCN targets including
E2F1 and E2F2, and neural stem cell markers including CD133, Musashi and Otx2 were down-
regulated in MLN8237-treated M10519 cells (Fig. 2B, 2C and S5 Fig.). Emergence of these
groups correlated with degradation of MYCN as determined by immunoblot analysis (Fig. 5B).
Finally, the effect of MLN8237 on MYCN pathways translated to survival extension in mice
bearing well-established tumors. In a survival study, we treated tumors continuously either
with vehicle or MLN8237. Mice in the untreated cohort developed lethal tumors within a
week, whereas mice in the treatment arm displayed significantly longer survival (Log-rank test,
P< 0.0001) (Fig. 5C). When we treated mice for 12 days with MLN8237, we observed again
longer survival compared to control (Log-rank test, P = 0.01) (S11 Fig.). Correlating with these
results, immunohistochemistry suggests that treatment of orthotopically-implanted tumors
with MLN8237 for 24 hours resulted in modest and dramatic reduction of MYCN and Ki67
levels, respectively (data not shown). These results correlated with our recent observation that
MLN8237 inhibited tumor growth and prolonged survival in medulloblastoma-bearing GTML
mice, which carry Trp53mutation [3].
Discussion
Here we show that GTML neurospheres represent a powerful tool for analysis of the molecular
mechanisms of MYCN-dependent transformation. They are also an efficient platform for in
vitro and in vivo pre-clinical evaluation of small molecule therapeutics for MYCN-driven MB.
GTML transgenic mice represent the only native model of MYC oncoprotein family-driven
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spontaneous medulloblastoma in which genetically manipulable tumors arise in immunocom-
petent mice with an intact blood-brain-barrier. In this context, it is important that MYCN-
driven GTML neurospheres retain the properties of primary tumors when sygeneically im-
planted in vivo. Other recent research into the genetic interaction between MYC or MYCN and
p53 has utilized non-natively arising orthotopic tumor implantation models in which either
cerebellar granule precursor cells or cerebellar stem cells (CD133+Lin-) were exogenously
transduced with either MYC or MYCN and were re-implanted orthotopically into mice
[47,48]. In the former publication, transduction of MYCN into cGNP yielded SHHmedullo-
blastoma, and in the latter, coexpression of MYCN with dominant negatively mutated p53 pro-
duced large-cell anaplastic medulloblastoma of multiple genetic subgroups. In common with
these models, expression microarray analysis has revealed that both the GTML and GTML/
Trp53KI/KI models represent Group3 disease [3,12,49]. Although MYCN amplifications are less
common than MYC in this subgroup, they are observed at an appreciable frequency, with rele-
vance in all non-WNT subgroups [6–10].
The finding that aggressive MB with features typical of non-SHH human MB is generated
by expansion of a highly proliferative and MYCN-dependent tumor-propagating cell that can
be maintained in culture and orthotopically transplanted is potentially important for the clini-
cal treatment of aggressive MB. The majority of these tumors are not defined by discrete genet-
ic changes or alterations in pathway signaling that are druggable. Our finding that growth of
tumor-propagating cells in this system are MYCN-dependent, and to some extent can be
forced to differentiate by targeted inhibition of MYCN, resulting in regression of tumors
Fig 5. Effect of MLN8237 on GTML spheres andmice. (A) PC projections of 96 cells fromWT1, WT2, M10519 cells treated with and without dox, and
M10519 cells with 100nMMLN8237. PC1 and PC2 captured 21% and 13% of variances in the dataset. (B) MYCN stability in MLN8237-treated M10519 cells.
Cells were incubated with dox or MLN8237, and cell extracts were analyzed by western blotting. (C) Kaplan-Meier curves for overall survival of mice having
orthotopic tumors treated with (red) or without MLN8237 (blue). 250 cells were transplanted in to the cerebellum of FBVNmice, and once the tumor burden
reached at a level of 1x109 photon/s, mice were daily treated twice with (n = 8) or without (n = 9) MLN8237 (daily oral dosing at 60mg/kg). Mice were treated
with MLN8237 for 5 days and then untreated for 2 days, and then the repeat this schedule twice more.
doi:10.1371/journal.pone.0119834.g005
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highlights the therapeutic potential of MYCN-targeted treatment approaches for patients with
aggressive MB. It should also be noted, however, that MYCN withdrawal only caused the cell
cycle arrest in GTML spheres and the temporal remission of orthotropic tumors in a tissue en-
vironment; we observed that prolonged (> 2 weeks) treatment of GTML mice with dox occa-
sionally resulted in the emergence of dox-resistant tumors (data not shown). Phenotypically,
the relapsed tumors resembled the original orthotopic tumors, expressing MYCN, Ki67, but
not GFAP in the presence of dox (data not shown). These results suggest that there appears to
be small number of cancer cells, in which MYCN expression is not controlled by rTA only. Al-
ternatively, dox may not be efficiently delivered to a part of tissues, from which the outgrowth
of new tumors may occur. Regardless of the mechanism, these results clearly suggest that tar-
geting MYCN with a single drug may only result in the short-term remission, and thus a com-
binatorial treatment with other drugs may be necessarily to eradicate cancer cells.
While GTML neurospheres appear to be a powerful tool to study the nature of cancer-prop-
agating cells, we found apparent inconsistencies in differentiation potential between cells cul-
tured as neurospheres or implanted orthotopically into the cerebellum. GTML cells retain
sphere morphology reminiscent of undifferentiated cells in culture in the presence of differenti-
ation inducers following MYCN withdrawal. In orthotopic tumors, we detected evidence of en-
hanced staining for markers associated with neuronal and glial differentiation. This
discrepancy can be explained by the fact that the latter was examined in a tissue environment,
while the former was examined in culture without any biological niche. Since we found that
MYCN withdrawal in GTML neurospheres results in the decrease of Nestin after 2 days, cer-
tain levels of differentiation may be triggered in dox-treated GTML cells. Culturing GTML
cells in a microenvironment that is permissive to differentiation, for example, with astrocytes
[50] may help establishing a more advanced pre-clinical system that recapitulates the nature of
tumor cells in a tissues environment.
Supporting Information
S1 Fig. Fine-tuning of tumor growth in the GTML system. (A) Simultaneous tissue specific
expression of humanMYCN and luciferase is driven by TRE-mediated expression in a target
mouse (TRE-MYCN-Luc, TML). Mating of single-transgenic TMLmice with those expressing
the Tetracycline transactivator (tTA) under the control of the Glutamate transporter (GLT1)
promoter (GLT1-tTA) provides CNS specificity confined to the hindbrain. Dox (Dox)-mediated
inhibition of TRE activation allows robust genetic control of MYCN and luciferase (Luc) expres-
sion. (B) Monitoring tumor growth through bioluminescence. Rapid tumor growth from days 81
to 99 is shown (C) M10519 cells were cultured and then incubated with luciferin, and then the lu-
ciferase signals were measured. The bioluminescence signal was correlated with the number of
spheres or cells. Error bars, ±SD. (D) Effect of growth factors (GF) on three GTML lines (M0983,
M14942, and M10519). Spheres were cultured with or without 20ng/ml of bFGF and EGF and
cell numbers were counted. Error bars, ±SD. (E) Re-entry to growth after removal of dox. Three
GTML lines (M0983, M21446, and M10519) were treated with dox for 7 days, and then cells
were cultured without dox. Error bars, ±SD. (F) Stability of MYCN and c-Myc proteins upon
dox treatment. Cell extracts fromM21446 GTML cells were examined by western analyses.
Spheres were cultured in the presence or absence of dox (1 or 3μg/ml) and harvested at 6 hours.
(TIF)
S2 Fig. Growth and differentiation characteristics of GTML spheres. (A) Effect of MYCN
withdrawal and differentiation inducers on M10519 GTML cells. M10519 GTML spheres were
cultured in neurobasal media with growth factors and either vehicle, dox (1μg/ml) or pro-
differentiation containing serum and retinoic acid (Diff. Media) as indicated and sphere
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formation and bioluminescence signals were monitored. Bar, 100μm. (B) Effect of serum and
dox on three GTML lines (M14942, M0982, and M10519) and wild type cells from the cerebel-
lum. Spheres were cultured for 8 days in neurobasal media with growth factors and either vehi-
cle, dox (1μg/ml), serum, or pro-differentiation containing serum and retinoic acid (Diff.
Media) as indicated. Bar, 100μm.
(TIF)
S3 Fig. Protein marker expression profiles in GTML spheres. (A) Impact of MYCN with-
drawal and differentiation inducers on marker expression in M10519 GTML cells. M10519
GTML spheres were cultured in neurobasal media with growth factors and either vehicle, dox
(1μg/ml) or pro-differentiation containing serum and retinoic acid (Diff. Media) as indicated.
(B) M10519 GTML spheres were treated with vehicle or dox for 7 days and expression of
Cleaved Caspase 3 and MYCN analyzed by immunofluorescence. Nuclei were counterstained
with DAPI. Bar, 50μm.
(TIF)
S4 Fig. Limiting-dilution sphere assay using M10519 cells. Serial dilutions (100, 10 and 1
cells per well) GTML cells were cultured in neurobasal media with B27 and growth factors. The
numbers of wells containing spheres were counted.
(TIF)
S5 Fig. Expression analysis of M10519 GTML cells.Heat map showing expression levels
(Cq values) of 96 genes. Indicated are wild-type cells from midbrain (WT1) or cerebellum
(WT2), untreated M10519 spheres (M10519), M10519 spheres treated with dox for 24 hours
(+Dox), or M10519 spheres treated with MLN8237 for 24 hours (+MLN8237). Mean expres-
sion values obtained from 96 single cells for each condition are shown.
(TIF)
S6 Fig. Single cell Expression analysis of M10519 GTML cells.Heat map showing expression
levels (Cq values) of 96 genes from single cells (n = 96 cells for each condition). Indicated are
wild-type cells from midbrain (WT1) or cerebellum (WT2), untreated M10519 spheres
(M10519), M10519 spheres treated with dox for 24 hours (M10519+Dox), or M10519 spheres
treated with MLN8237 for 24 hours (M10519+MLN8237).
(TIF)
S7 Fig. Characterization of GTML spheres by orthotopic implantation. (A) Serial dilutions
of M10519 GTML cells (passage 10–27) were implanted into the cerebellum of immunocompe-
tent (FVB/N) mice: n = 10 (for 1000, 5000, 1000, 250, and 100 cells); n = 9 (for 50 and 25 cells);
n = 10 for tumor cells implanted without in vitro expansion. Tumor incidence was evaluated
by monitoring bioluminescence twice per week. (B) Kaplan-Meier curve showing overall sur-
vival of mice implanted with M14942 (blue, passage 11, n = 5), and M10519 (red, passage 10,
n = 5) cells. 250 cells were implanted orthotopically per site.
(TIF)
S8 Fig. Tumor-propagating potential of FACS-sorted CD15+ cells. (A) Sorting of CD15+
and CD15- populations fromM21446 GTML cells by FACS. (B, C) Kaplan-Meier curves for
overall survival of mice implanted with CD15+ or CD15- cells from (B) M21446 (passage 20)
and (C) M0983 (passage 10) cells. 10 cells were implanted into the cerebellum per mouse (n = 5
for each). (D) Sphere assays using FACS-sorted CD15+ and CD15- cells (M10519 cells, passage
18). 50 cells per well were plated onto a 24-well plate containing neurobasal media in the pres-
ence of growth factors and collagen (1mg/ml) and then cultured for four weeks.
(TIF)
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S9 Fig. Tumor-propagating potential of FACS-sorted CD133+ cells. (A) Sorting of CD133+
and CD133- populations fromM10519 GTML cells (passage 23) by FACS. Cells were incubat-
ed with control IgG1 or anti-CD133 conjugated with PE prior to sorting. (B) Kaplan-Meier
curve showing overall survival of mice implanted with CD133+ or CD133- cells. 10 cells were
implanted into the cerebellum per mouse (n = 5 for each). (C) 3D neurosphere assays using
FACS-sorted CD133+ and CD133- cells (M10519, passage 23). 50 cells per well were plated
onto a 24-well plate containing neurobasal media in the presence of growth factors and colla-
gen (1mg/ml) and then cultured for four weeks.
(TIF)
S10 Fig. Hierarchical clustering analysis of GTML following treatment with dox or
MLN8237. “M10519” cluster (black), “M10519+dox” cluster (green), and “M10519+MLN8237
plus M10519+Dox cluster” (blue) are shown.
(TIF)
S11 Fig. Effect of MLN8237 on GTML mice. Kaplan-Meier curves for overall survival of mice
bearing orthotopic tumors treated with MLN8237 (red) or vehicle (blue). 250 cells (M10519
cells, passage 16) were transplanted into the cerebellum of FBVN mice and treatment initiated
when tumor-associated bioluminescence signal reached 1x109 photon/s. Mice were treated by
oral gavage (30mg/kg twice daily) with MLN8237 (red, n = 4) or vehicle (blue, n = 4). Mice
were treated with MLN8237 or vehicle for a period 12 days as indicated by grey shading.
(TIF)
S1 Table. List of 96 genes with primer sequences used in BioMark qPCR.
(XLSX)
S2 Table. Characteristics of GTML tumor-derived neurosphere cell lines.
(DOCX)
S3 Table. BioMark qPCR expression data.
(XLSX)
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